Patrick Loustau M.S., M.A.,
President and Chief Executive Officer

Patrick joined Granite Bio as President and CEO in February 2025.

He brings broad and successful experience in building and developing organizations and strategy in Biotech and Pharmaceutical companies. Patrick has led significant buy and sell side transactions and has demonstrated partnership and transformational leadership skills. He has led and contributed to $350M private and public capital raising.

Prior to Granite Bio, Patrick spent 5 years at Amolyt Pharma where he initiated and led the M&A efforts that resulted in the acquisition of Amolyt by AstraZeneca for $1.05B. He significantly contributed to the Series B and C financing and negotiated several research collaboration and in-licensing agreements while leading PR, IR, Medical Affairs, KOL development, and Commercial.

Prior to joining Amolyt Pharma, from 2017-2019, Patrick was the CEO of Zumbro Discovery, Inc., a clinical stage biotechnology company. From 2014-2016, he was the President of Zafgen, Inc., a Boston-based biotechnology company focused on rare metabolic disease indications. Patrick was the SVP of Global Commercialization, Cardiovascular and Metabolics for Bristol-Myers Squibb from 2010-2014 and worked for 14 years for Novo Nordisk where he had several roles of increasing responsibility most recently as SVP Global Marketing and Medical Affairs. Patrick attended The General Manager Program, Harvard Business School and holds M.S. and M.A. degrees in Human Resources/Marketing and in Psychology and a B.A. in Physiology.